8 October 2018 - - The US Food and Drug Administration has approved US-based biopharmaceutical company Coordination Pharmaceuticals, Inc.'s Investigational New Drug application to initiate a first-in-human Phase 1 clinical study of CPI-100 in patients with advanced tumors, the company said.

CPI-100 is a structurally optimal core-shell nanoparticles based on CPI's proprietary nanoscale coordination polymer platform technology to selectively deliver immunostimulatory chemotherapeutic combinations to tumors, providing a new approach to initiate and stimulate immune-mediated eradication of cancer cells using synergistic nanomedicines.

Coordination Pharmaceuticals is a privately held oncology drug development company that aims to address unmet medical needs and improve patient care.

Its NCP technology is in-licensed from the University of Chicago with worldwide rights in development and commercialisation.